The high-density lipoprotein (HDL) hypothesis was arguably damaged by the negative outcome of the AIM-HIGH study of Abbott Laboratories Inc.’s Niaspan (long-acting niacin) on top of simvastatin or simvastatin and ezetimibe (Merck & Co. Inc.’s Zetia). That study therefore indirectly raises questions about the premise underlying the role of cholesterylester transfer protein (CETP) inhibitors, which some companies are betting could be the next big advance in lipid management.
The outcomes study of about 3,300 patients with a history of cardiovascular disease and with well-controlled low-density lipoprotein (LDL) was...
